Idiopathic pulmonary fibrosis treatment possible with PirfenidoneOnce-a-day dose of Pirfenidone could prove effective for patients struggling with idiopathic pulmonary fibrosis (IPF), according to researchers from Japan.

Daily doses of the drug can be useful to slowdown progression of idiopathic pulmonary fibrosis and reducing the loss of lung capacity, as per the Phase III, double-blind, placebo-controlled clinical trial.

Results of the trial were presented at the American Thoracic Society’s International Conference in Toronto.